Xell

Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG in July 2021. Xell develops, produces, and markets media and feed supplements for cell cultures, especially for manufacturing viral vectors that are used in gene therapeutics and vaccines. Beyond these media, the company offers various analytical services for characterizing, screening, and quantifying media components, as well as for optimizing media composition.